MET and neoplasm: In these mice, combined treatment with cabozantinib, which targets c-Met, and the dual mTOR inhibitor MLN0128, which targets activated β-catenin effectors, leads to tumor regression, whereas cabozantinib or MLN0128 monotherapy does not (152).